There have been talks about what would happen
once UK leaves EU which has put lot of QPPV (Qualified Persons Responsible for
Pharmacovigilance) in UK in dilemma as the regulations say that the QPPV should
be a part of the EU, with the impact Brexit it will hit the pharmacovigilance
system in UK as EU would not be obliged to carry out Post marketing
surveillance in UK.
Currently June Raine who is chairing the
Pharmacovigilance Risk Assessment Committee ( part of the European Medical
Agency, in which there are two members from each member state) is from the
Medicines and healthcare products regulatory agency (MHRA) of the UK.
There have been discussions about QPPV who
still want to be a part of EU which might eventually lead to a negotiation
between EMA and UK to collaborate pharmacovigilance activities together, as
pharmacovigilance is above politics.
By Joseph Mathew
Sr. Manager- Think i
About us:
We are an organization providing
technological solutions and result oriented quality services in
Pharmacovigilance, Clinical Trials, Medical Writing, Drug Regulatory Affairs
and Human Resources.
We provide cloud based software solutions for pharmacovigilance
which are not only cost effective and user friendly but also fully validated
for quick, easy import, entry and electronic submissions of adverse
event.
For more details, contact us at +91 9560102587
or +91 9810068241
No comments:
Post a Comment